H & M Hennes & Mauritz AB: 2 directors

A director at H & M Hennes & Mauritz AB bought 1,990,000 shares at 173.942SEK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS sold 9,000 shares at 915.500DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

AcadeMedia AB (Buy, TP: SEK65.00) - Finnish market entry

Q3 was solid, with growth, profit and FCF driven by volume and price. The Touhula acquisition appears value-enhancing and AcadeMedia’s recent share redemption makes sense, now starting to address its track record of weak capital allocation. We see a solid demand outlook and an attractive valuation, and reiterate our BUY. We have raised our target price to SEK65 (63), still implying no near-term multiples expansion.

On the right track again

Profitability is on the rise. More to come when utilisation improves. Reiterate BUY, new TP of SEK 85 (80).

Strong Q3 numbers

Novo Nordisk (Buy, TP: DKK1100.00) - Small guidance raise

Q1 LCY figures beat consensus due to US rebate adjustments related to 2023 adding c5%-points to LCY growth and low SG&A cost boosting EBIT growth in Q1. Wegovy sales were below consensus but above our forecast, and we have therefore adjusted our rebate assumptions for 2024. The 2024 guidance was raised to LCY sales growth of 19–27% (18–26%) and LCY operating profit growth of 22–30% (21–29%). We reiterate our BUY and DKK1,100 target price.

Novo Nordisk (Buy, TP: DKK1100.00) - Company consensus added

We are slightly below consensus on Q1e LCY sales growth (we forecast 19.4%, consensus 21.4%) and LCY operating profit growth (we forecast 16.8%, consensus 19.5%), due to lower expected Wegovy sales. However, we believe the Ozempic US prescription trend will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.

Alimak (Hold, TP: SEK102.00) - Facade Access progress

Alimak reported a solid Q1, with strong margins in Industrial and Facade Access. Margins in Construction were on the weak side (following weak Q4 orders), but management seemed confident of a return to normal as soon as in Q2. We have raised our 2024–2026e adj. EBITA by 1–2%. We reiterate our HOLD, but have raised our target price to SEK102 (100).

Alimak (Hold, TP: SEK100.00) - Limited changes ahead of Q1

We have lowered our 2024e sales and adj. EBITA by 1%, mainly on lower organic growth in Construction, and marginally revised our 2025–2026e ahead of the Q1 results (due at 08:00 CET on 25 April). We believe project delays within Facade Access continued to hamper divisional sales, and expect a recovery in H2. We reiterate our HOLD, but have raised our target price to SEK100 (94) on valuation.

Novo Nordisk (Buy, TP: DKK1100.00) - Ozempic to drive raised guidance

We are slightly below consensus on Q1 LCY sales growth (we forecast 19.4%, consensus 20.1%) and LCY operating profit growth (we forecast 16.8%, consensus 17.3%), due to lower expected Wegovy sales. However, we believe the trend in Ozempic US prescriptions will prompt management to raise the 2024 guidance to LCY sales growth of 20–28% (18–26%) and LCY operating profit growth of 23–31% (21–29%). We reiterate our BUY and DKK1,100 target price.

Hennes & Mauritz (Buy, TP: SEK200.00) - 10% EBIT-margin target in its ...

A strong start to 2024, and spring sales with solid gross margins, have boosted confidence in H&M’s near-term 10% EBIT margin target. We like the store-refurbishment acceleration too, supporting our view of it returning to store growth in 2025e. We reiterate our BUY, but have raised our target price to SEK200 (180) on higher forecasts.

H&M : Good results on the back of outperformance from COGS

>Higher gross margin more than offsets in-line sales and higher opex… - H&M’s Q1 2024 results were ahead of our and consensus estimates (EBITDA 9.4% above consensus and 7.8% above our estimates) due to stronger tailwinds from COGS (5.8% lower than estimated) and despite in-line sales in the quarter (0.6% above consensus and 0.6% below our estimates). The better performance from COGS fed through to the rest of the P&L, obviously with a positive leverage effect, le...

Retail Sector Report - ReTales Q4 2023

Retail Sector Report - ReTales Q4 2023

Retail Sector Report - ReTales Q4 2023

Retail Sector Report - ReTales Q4 2023

Hennes & Mauritz (Buy, TP: SEK180.00) - Strong Q1

We consider this a positive report for H&M, including EBIT 53% above consensus, a reiterated 2024 EBIT margin target, and decent start to spring sales. We expect consensus 2024e adj. EBIT to come up by 5%+ on the back of the Q1 report, and believe a positive share price reaction is warranted.

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/26/2024

...

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 26/03/2024

...

H&M : Top line growth is key and necessary for an inflection point

>We are lowering our estimates after disappointing results in the last quarters, especially in Q4 2023, showing the challenges faced by the company… - We continue to think that H&M needs a significant change in its model in order not to lose market share, and that the results published over the last few quarters are testimony of the difficulty in achieving such transformation. The decline in sales in the last reported quarter, as well as the negative top line growth p...

Novo Nordisk (Buy, TP: DKK1100.00) - Raising the bar with amycretin

At its CMD, the company maintained its strategic aspirations for 2025. It also expects increasing operating profit margins in the coming years. A key focus was the phase I trial results for amycretin in obesity, showing 13.1% weight loss (no signs of plateau). While not confirmed, we still expect it to go directly to phase III development. We reiterate our BUY and have increased our target price to DKK1,100 (1,000) on higher pipeline valuation.

Novo Nordisk (Buy, TP: DKK1000.00) - Catalent: game changer

We believe the move by Novo Holding to acquire Catalent and re-sell the three fill-finish facilities to Novo Nordisk is inspired, and underpins the strength of having the foundation as a major shareholder. With the acquisition, the obesity opportunity moves from supply to demand-driven, while at the same time making scale a significant competitive advantage. We have upgraded to BUY (HOLD) and raised our target price to DKK1,000 (800).